%0 English Abstract
%T [Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas].
%A Melegh Z
%A Csernák E
%A Kohánka A
%A Rubovszkyné Gallai M
%A Bencze E
%A Szőke M
%A Pap L
%A Simon A
%A Küronya Z
%A Biró K
%A Géczi L
%A Tóth E
%J Magy Onkol
%V 68
%N 2
%D 2024 Jul 16
%M 39013087
暂无%X The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology diagnostics. Among 281 patients with prostate adenocarcinoma, somatic pathogenic mutations in one of these genes were identified in 21.4% of patients. In 28.5% of the patients, the test was unsuccessful; the main limitation of successful testing was the age of the paraffin blocks and low DNA concentration. In the case of BRCA1/2 testing, the success rate was significantly reduced for samples older than 5 years, while in tests involving a broader set of homologous recombination repair genes, the success rate was significantly reduced for samples older than 2 years. Therefore, it is very important to test high-risk prostate cancers at the time of primary diagnosis, and probably also liquid biopsy testing of circulating tumor DNA will play an important role in safe diagnosis in the near future.